Mateon Therapeutics (OTCMKTS:MATN – Get Free Report) and Spruce Biosciences (NASDAQ:SPRB – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.
Earnings & Valuation
This table compares Mateon Therapeutics and Spruce Biosciences”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Mateon Therapeutics | N/A | N/A | -$6.64 million | ($0.02) | -2.73 |
| Spruce Biosciences | $4.91 million | 14.70 | -$38.97 million | ($36.60) | -1.44 |
Analyst Recommendations
This is a summary of current recommendations and price targets for Mateon Therapeutics and Spruce Biosciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mateon Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
| Spruce Biosciences | 1 | 2 | 5 | 0 | 2.50 |
Spruce Biosciences has a consensus price target of $186.60, indicating a potential upside of 254.08%. Given Spruce Biosciences’ stronger consensus rating and higher possible upside, analysts plainly believe Spruce Biosciences is more favorable than Mateon Therapeutics.
Profitability
This table compares Mateon Therapeutics and Spruce Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Mateon Therapeutics | N/A | -64.66% | -42.92% |
| Spruce Biosciences | N/A | -155.40% | -101.67% |
Volatility & Risk
Mateon Therapeutics has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 3.26, indicating that its stock price is 226% more volatile than the S&P 500.
Insider & Institutional Ownership
0.1% of Mateon Therapeutics shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 39.2% of Mateon Therapeutics shares are held by company insiders. Comparatively, 4.3% of Spruce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Spruce Biosciences beats Mateon Therapeutics on 7 of the 12 factors compared between the two stocks.
About Mateon Therapeutics
Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.
About Spruce Biosciences
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
